Animal studies may provide a close approximation to humans when addressing the key challenge of clinical translatability. In the preclinical setting, new insights into disease models and mechanisms are crucial to efficacy studies. In this webinar, we will share our experiences and insights of the mechanistic aspects of preclinical pharmacology in the areas of neurodegenerative diseases, NASH, and metabolic disorders (involving PCSK9, in particular). Additional discussion will focus on how such insights are used in testing new modalities such as oligonucleotides and AAV that target the CNS or the liver.
Key Learning Objectives:
- Review spontaneous Alzheimer-like dementia, diet-induced NASH and other metabolic diseases in small and large animals
- Dive into the clinical relevance of NASH models and insight into hepatic fibrosis
- Learn how PCSK9 expression levels and/or activity are affected under metabolic induction
- See how these mechanistic insights can help in testing new modalities
Who Should Attend:
- Project Managers in Drug Discovery
- Program Leaders and Directors of Drug Discovery
- Scientists in Drug Discovery, including Medicinal Chemists, In Vivo Biologists in Neurodegenerative Diseases and NASH and other Metabolic Diseases, Pharmacologists, etc.
- Scientists who are interested in new modality therapies